Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Breast Cancer
Breast Cancer
Advanced Breast Cancer
Endometrial Cancer

Interventions: Drug: LY3484356
Drug: Everolimus
Drug: Abemaciclib
Drug: Alpelisib
Drug: Aromatase Inhibitor (AI)
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2019-12-06

Last Posted Date: 2024-08-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 500

Registration Number: NCT04188548

Locations: 🇺🇸
Winship Cancer Center Emory University, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 69 locations

A Study of LY3526318 in Healthy Women

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3526318

First Posted Date: 2019-12-03

Last Posted Date: 2020-03-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT04183283

Locations: 🇧🇪
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Phase 3

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2019-12-03

Last Posted Date: 2024-08-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2539

Registration Number: NCT04184622

Locations: 🇺🇸
National Research Institute - Wilshire, Los Angeles, California, United States
🇺🇸
University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸
Clinvest Research LLC, Springfield, Missouri, United States

and more 114 locations

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Biological: Lebrikizumab
Other: Placebo

First Posted Date: 2019-11-26

Last Posted Date: 2023-05-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 445

Registration Number: NCT04178967

Locations: 🇺🇸
University Clinical Trials, Inc., San Diego, California, United States
🇺🇸
Dermatology Associates, Seattle, Washington, United States
🇧🇬
Military Medical Academy, Sofia, Bulgaria

and more 86 locations

A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3493269 - SC
Drug: Placebo - SC
Drug: LY3493269 - IV

First Posted Date: 2019-11-26

Last Posted Date: 2020-05-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 33

Registration Number: NCT04178733

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tirzepatide
Drug: EE/NGM

First Posted Date: 2019-11-21

Last Posted Date: 2023-03-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT04172987

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2019-11-18

Last Posted Date: 2024-04-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 196

Registration Number: NCT04166773

Locations: 🇺🇸
Texas Diabetes & Endocrinology, P.A., Round Rock, Texas, United States
🇯🇵
Kumamoto Shinto General Hospital, Kumamoto, Japan
🇺🇸
Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina, United States

and more 105 locations

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Phase 1

Terminated

Conditions: Advanced Solid Tumor
Colorectal Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: LY3499446
Drug: Docetaxel
Drug: Abemaciclib
Drug: Cetuximab
Drug: Erlotinib

First Posted Date: 2019-11-15

Last Posted Date: 2021-11-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 5

Registration Number: NCT04165031

Locations: 🇦🇺
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Indiana Univ Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 1 locations

A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: LY900027
Drug: Insulin Lispro

First Posted Date: 2019-11-13

Last Posted Date: 2020-08-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT04161976

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Phase 1

Withdrawn

Conditions: Advanced Cancer

Interventions: Drug: LY3200882
Drug: Pembrolizumab

First Posted Date: 2019-11-12

Last Posted Date: 2020-02-19

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT04158700

Locations: 🇪🇸
Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Hospital Madrid Norte Sanchinarro, Madrid, Spain
🇪🇸
Hospital Clinic I Provincial, Barcelona, Spain

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy